Victoza Outperforms Byetta In Head-To-Head Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Head-to-head trial results presented at the American Diabetes Association meeting are positive, but safety questions aren't likely to go away.
You may also be interested in...
Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
Once-a-day here to stay? With once-weekly taspoglutide just officially rejected by Roche and long-lasting Bydureon delayed on safety, Zealand CEO talks up the virtues of QD GLP-1 analogs.
Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
Once-a-day here to stay? With once-weekly taspoglutide just officially rejected by Roche and long-lasting Bydureon delayed on safety, Zealand CEO talks up the virtues of QD GLP-1 analogs.
Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
Sanofi-Aventis and Zealand Pharma have gained some ammunition as they prepare to enter the competitive GLP-1 agonist market, with data from a head-to-head study showing their lixisenatide to be non-inferior to Lilly/Amylin's Byetta (exenatide).